Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Share-based Compensation (2019 - 2023)

Alx Oncology Holdings' Share-based Compensation history spans 5 years, with the latest figure at $6.7 million for Q4 2023.

  • For Q4 2023, Share-based Compensation rose 6.77% year-over-year to $6.7 million; the TTM value through Dec 2023 reached $26.3 million, up 10.21%, while the annual FY2025 figure was $12.6 million, 53.57% down from the prior year.
  • Share-based Compensation for Q4 2023 was $6.7 million at Alx Oncology Holdings, down from $7.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.0 million in Q3 2023 and bottomed at $75000.0 in Q4 2019.
  • The 5-year median for Share-based Compensation is $4.8 million (2021), against an average of $3.8 million.
  • The largest annual shift saw Share-based Compensation surged 2224.0% in 2020 before it fell 2.74% in 2021.
  • A 5-year view of Share-based Compensation shows it stood at $75000.0 in 2019, then soared by 2224.0% to $1.7 million in 2020, then skyrocketed by 226.22% to $5.7 million in 2021, then grew by 10.71% to $6.3 million in 2022, then grew by 6.77% to $6.7 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Share-based Compensation are $6.7 million (Q4 2023), $7.0 million (Q3 2023), and $6.2 million (Q2 2023).